MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jac/dkag233

Медицинская библиотека · The Journal of antimicrobial chemotherapy · 2026

Subtherapeutic posaconazole exposure during delayed-release tablet prophylaxis in high-risk patients with haematological malignancies: rationale for routine therapeutic drug monitoring.

Urbancic Karen F, Yong Michelle K, Yong KarYee, Page Hayley, Stewart Marcelle, Ritchie David, Bajel Ashish, Wong Eric, Fong Chun, Trubiano Jason A, Kong David C M, Slavin Monica A

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Posaconazole prophylaxis is indicated in high-risk patients with haematological malignancies to prevent invasive fungal diseases (IFDs) with guidelines advising steady-state posaconazole plasma concentrations (PPCs) above 0.5-0.7 mg/L. Therapeutic drug monitoring (TDM), however, is not routinely recommended for posaconazole delayed-release tablet (DRT) prophylaxis.

OBJECTIVES

To describe PPCs in hospitalized high-risk patients with haematological malignancies treated for AML or undergoing allogeneic haematopoietic cell transplantation receiving posaconazole prophylaxis with posaconazole DRT and factors influencing exposure.

PATIENTS AND

METHODS

This prospective, two-centre cohort study measured serial PPCs at Days 7, 14 and 21, and during diarrhoea episodes in adult high-risk patients receiving prophylaxis with posaconazole DRT between August 2019 and May 2023. Patients were followed during hospital admission and for 7 days after the last dose of posaconazole or hospital discharge.

RESULTS

Ninety-two patients contributed 223 PPCs. Subtherapeutic PPCs (<0.7 mg/L) occurred in 77 (34.5%) samples and 49 (53.3%) patients recorded ≥1 subtherapeutic PPC. The median Day 7 PPC was 0.84 (IQR: 0.47-1.16) mg/L, with no significant changes over time. In patients with diarrhoea compared with no diarrhoea, the median PPC was significantly lower [0.74 (IQR: 0.48-1.00) mg/L versus 0.92 (IQR: 0.64-1.40) mg/L, P = 0.007]. Multivariate analysis identified older age (>60 years) was protective against subtherapeutic PPCs. Six IFDs developed in five patients (5.4%) during follow-up and posaconazole-attributed hepatotoxicity resulted in cessation for one patient (1.1%).

CONCLUSIONS

Subtherapeutic PPCs are common during posaconazole DRT prophylaxis, suggesting the need for routine TDM to optimize dosing in those receiving this posaconazole formulation.

Для цитирования: Urbancic Karen F, Yong Michelle K, Yong KarYee, Page Hayley, Stewart Marcelle, Ritchie David, Bajel Ashish, Wong Eric, Fong Chun, Trubiano Jason A, Kong David C M, Slavin Monica A. Subtherapeutic posaconazole exposure during delayed-release tablet prophylaxis in high-risk patients with haematological malignancies: rationale for routine therapeutic drug monitoring.. The Journal of antimicrobial chemotherapy. 2026. DOI: 10.1093/jac/dkag233.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.